The first late-stage test of an LSD-based medicine for generalized anxiety disorder has reported a positive result. Definium Therapeutics said its Phase 3 Voyage study met its primary endpoint, with a single dose producing a larger reduction in anxiety symptoms than placebo at 12 weeks.
The company reported in its topline announcement that the least-squares mean change in the Hamilton Anxiety Rating Scale at week 12 was a drop of 11.6 points among participants who received DT120, an orally disintegrating tablet formulation of lysergide, compared with a drop of 6.2 points in the placebo group. That is a placebo-adjusted difference of 5.4 points, which the company reported as statistically significant with a standardized effect size of 0.81.
